CD55 and pancreatic intraductal papillary-mucinous neoplasm: Accordingly, CD55 was chosen as a validation target of IPMN dysplasia for 3 main reasons: (1) It was highly expressed in all (100%, 5/5) invasive IPMN samples (Figure 4), (2) it had the smallest p-value of all potential markers from all comparative groups that involved invasive IPMN (Figure 5, Table S6), and (3) it had the highest fold-change between comparisons 2 (HGD vs. invasive IPMN) and 3 (LGD vs. invasive IPMN) (Figure 3).